Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Cardinal Health, Inc.

Finance Watch: Big Financings Show Investors Remain Interested In Certain Opportunities

A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.

Financing Growth

Finance Watch: FibroGen, Amarin And Others Downsize To Survive

Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.

Restructuring Business Strategies

The Quality Lowdown: As Washington Churns On Drug Shortages, Supply Chain Challenges Grow

While FDA commissioner meets with firms on shortages, senators challenge alternative source of platinum chemotherapies, FDA hinges imports from Sun plant on successful media fill runs, Safe Chain warned on Biktarvy suppliers, and the FDA asks Ipca more questions while setting “Mr. Ye” straight.

Supply Chain Quality

Aldeyra Thinks It May Have Broadly Applicable Retinitis Pigmentosa Therapy

Data from a small Phase II study show that Aldeyra’s methotrexate formulation may address the underlying cause of 20%-30% of RP cases. The drug recently was denied US FDA approval in a rare ocular cancer.

Clinical Trials Drug Approval Standards
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Distributors
  • Medical Devices
  • Services
  • Services
    • Home Infusion
    • Hospitals, Nursing Homes, Institutions
    • Pharmacy Services, PBMs
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Other Names / Subsidiaries
    • AccessClosure
    • Allegiance Healthcare Corporation
    • Cordis Corporation
    • Innovative Therapies, naviHealth
    • OutcomesMTM
    • The Harvard Drug Group
    • VIASYS Healthcare
UsernamePublicRestriction

Register